{"protocolSection": {"identificationModule": {"nctId": "NCT02152384", "orgStudyIdInfo": {"id": "15406"}, "secondaryIdInfos": [{"id": "I2R-MC-BIDU", "type": "OTHER", "domain": "Eli Lilly and Company"}], "organization": {"fullName": "Eli Lilly and Company", "class": "INDUSTRY"}, "briefTitle": "A Study to Compare and Measure the Effects of Insulin Peglispro (LY2605541) and Glargine on Meal Time Insulin Requirements", "officialTitle": "The Effect of Treatment With Basal Insulin Peglispro or Insulin Glargine on the Dose Response Effect of Prandial Insulin Lispro in Patients With Type 1 Diabetes Mellitus."}, "statusModule": {"statusVerifiedDate": "2018-10", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-06"}, "primaryCompletionDateStruct": {"date": "2014-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2014-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-05-28", "studyFirstSubmitQcDate": "2014-05-28", "studyFirstPostDateStruct": {"date": "2014-06-02", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2018-03-17", "resultsFirstSubmitQcDate": "2018-10-29", "resultsFirstPostDateStruct": {"date": "2019-03-01", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2018-10-29", "lastUpdatePostDateStruct": {"date": "2019-03-01", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Eli Lilly and Company", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study will look into how a base dose of insulin peglispro and insulin glargine will affect the meal time dose and efficacy of insulin lispro in type 1 diabetics."}, "conditionsModule": {"conditions": ["Diabetes Mellitus, Type 1"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "BASIC_SCIENCE", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 28, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Insulin peglispro (LY2605541, with Insulin Lispro)", "type": "EXPERIMENTAL", "description": "Insulin peglispro (LY2605541) once daily subcutaneous (SC) injection at bedtime. Insulin lispro given SC prandially or as bolus as required", "interventionNames": ["Drug: Insulin Peglispro", "Drug: Insulin Lispro"]}, {"label": "Insulin Glargine (with Insulin Lispro)", "type": "ACTIVE_COMPARATOR", "description": "Insulin glargine once daily SC injection at bedtime. Insulin lispro given SC prandially or as a bolus as required", "interventionNames": ["Drug: Insulin Lispro", "Drug: Insulin Glargine"]}], "interventions": [{"type": "DRUG", "name": "Insulin Peglispro", "description": "Administered SC", "armGroupLabels": ["Insulin peglispro (LY2605541, with Insulin Lispro)"], "otherNames": ["LY2605541"]}, {"type": "DRUG", "name": "Insulin Lispro", "description": "Administered SC", "armGroupLabels": ["Insulin Glargine (with Insulin Lispro)", "Insulin peglispro (LY2605541, with Insulin Lispro)"]}, {"type": "DRUG", "name": "Insulin Glargine", "description": "Administered SC", "armGroupLabels": ["Insulin Glargine (with Insulin Lispro)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Pharmacodynamics (PD): Plasma Glucose Area Under the Concentration Curve Zero Through 5 Hours (AUC 0-5h), Above Pre Meal Baseline for Insulin Lispro", "description": "To quantitate the pharmacodynamic (PD) effect of a range of prandial insulin lispro doses after treatment with insulin peglispro (LY2605541) compared to insulin glargine during a meal tolerance test (MTT), with sequenced doses of insulin lispro ranging from 25% to 150% of each participant's normal dose. Data presented as hours times milligrams per deciliter (mg\\*h/dL)", "timeFrame": "Day 30, 31, 32, 33, 34, pre-breakfast and10,20,30,40,50,60,90,120,150,180,210,240,270, 300 minutes (5 hours) post-breakfast"}], "secondaryOutcomes": [{"measure": "Pharmacokinetics (PK): Under the Concentration Curve Zero Through 5 Hours (AUC 0-5h) for Prandial Insulin Lispro", "description": "Abbreviation for hours times picomol per liter (pmol\\*h/L)", "timeFrame": "Day 29: Pre-breakfast, and 15, 30, 45, 60, 90, 120, 150,180,210,270, and 300 minutes (5 hours) post-breakfast"}, {"measure": "Pharmacodynamics (PD): Average Glucose Infusion Rate From Euglycemic 2-step Hyperinsulinemic Clamp (M-value)", "description": "Abbreviation for micro mole per kilogram per minute (\u00b5mol/kg/min). Both arms received insulin lispro in addition to their respective study drug. During the euglycemic 2-step hyperinsulinemic clamp, both low and high insulin was infused sequentially during the same procedure. The 2-step clamp procedure allowed insulin sensitivity to be measured in participants and uses a lower dose of insulin of which the effect is largely on the liver and a high dose of insulin at which the effect has reached 100% on liver and effects are largely on glucose uptake in peripheral tissues. Measurements for average glucose infusion rate are collected for both steps (low and high) of the clamp procedure.", "timeFrame": "Day 35, last 60 minutes of euglycemic 2-step hyperinsulinemic clamp"}, {"measure": "Pharmacokinetics (PK): Area Under the Concentration Curve From Time Zero to Last Time (AUC [0 Tlast]) for Paracetamol", "timeFrame": "Day 29: Pre-breakfast, and 15, 30, 45, 60, 90, 120, 150,180,210,270, and 300 minutes (5 hours) post-breakfast"}, {"measure": "Appetite and Satiety Ratings, as Measured Using Visual Analog Scale (VAS) on Day 29", "description": "VAS was scored from 0 - 100 millimeters (mm) as a perception of appetite and satiety (Flint et al. 2000), 0 being not hungry at all or nothing at all and 100 being extremely hungry and extremely large amount.\n\nThe questions are abbreviated in table from: How hungry do you feel right now? to Hunger and How much food do you think you could eat right now? to Food amount.\n\nDay 29 and cumulative insulin lispro doses of 25%, 50%, 75%, 100% and 150 % of normal insulin lispro dose included.Scores were averaged will be presented and calculated by a sum of the scores dividing by the total by the number of scores reported for timepoints and reported in millimeters.", "timeFrame": "Day 29:Upon waking, pre-breakfast, 1 hour (hr), 2 hr, 3 hr, 4 hr and 5 hr post breakfast"}, {"measure": "Pharmacodynamics (PD): Area Under the Concentration Zero Through 5 Hours (AUC 0-5h) for Triglycerides", "timeFrame": "Day 29, predose and 15, 30, 45, 60, 90, 120, 150,180,210,270, and 300 minutes (5 hours) post-breakfast"}, {"measure": "Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) for Insulin Lispro During Clamp", "description": "During the euglycemic 2-step hyperinsulinemic clamp, both low and high insulin was infused sequentially during the same procedure. The 2-step clamp procedure allowed insulin sensitivity to be measured in participants and uses a lower dose of insulin (Low) of which the effect is largely on the liver and a high dose of insulin (high) at which the effect has reached 100% on liver and effects are largely on glucose uptake in peripheral tissues. AUC is taking during infusion for this outcome measure.", "timeFrame": "Day 35, insulin clearance during lispro infusion (dosing=infusion)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Have a stable (within 0.5 percent (%) from last measure) glycated hemoglobin (HbA1c) \\<9.0%\n* Have a stable (within 30%) basal insulin dose of 0.2 to 1.0 units per kilogram per day (U/kg/day) and a total daily insulin dose (basal + prandial/bolus) \\<1.5 units per kilogram (U/kg)\n* Have C-peptide \\<0.3 nanomoles per liter (nmol/L)\n* Are able and willing to eat the protocol specified standard breakfast and other meals as required\n\nExclusion Criteria:\n\n* Have corrected QT interval (QTc) prolongation \\>500 milliseconds (ms) or have any other abnormality in the 12 lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study\n* Have an abnormal blood pressure as determined by the investigator\n* Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine (apart from Type 1 Diabetes Mellitus \\[T1DM\\]), hematological, or neurological disorders\n* Have fasting triglycerides (TGs) \\>400 milligrams per deciliter (mg/dL) (4.52 micromoles per liter \\[mmol/L\\])\n* Have used systemic corticosteroids within 4 weeks prior to randomization\n* Currently receive insulin pump or insulin degludec\n* Have poorly controlled diabetes or are known to have poor awareness of hypoglycemia\n* Have history of gastroparesis or gastrointestinal malabsorption\n* Require treatment with any drug other than insulin to treat diabetes\n* Have a previous history of proliferative retinopathy", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", "affiliation": "Eli Lilly and Company", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Neuss", "zip": "41460", "country": "Germany", "geoPoint": {"lat": 51.19807, "lon": 6.68504}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Treatment Sequence A/B", "description": "Treatment A: Insulin peglispro (LY2605541) once daily subcutaneous (SC). Insulin lispro given SC prandially or as bolus as required\n\nTreatment B: Insulin glargine once daily subcutaneous (SC). Insulin lispro given SC prandially or as bolus as required"}, {"id": "FG001", "title": "Treatment Sequence B/A", "description": "Treatment B: Insulin glargine once daily subcutaneous (SC). Insulin lispro given SC prandially or as bolus as required\n\nTreatment A: Insulin peglispro (LY2605541) once daily subcutaneous (SC). Insulin lispro given SC prandially or as bolus as required"}], "periods": [{"title": "Run In (1-5 Week Transition)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "14"}, {"groupId": "FG001", "numSubjects": "14"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "14"}, {"groupId": "FG001", "numSubjects": "14"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Period 1", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "14"}, {"groupId": "FG001", "numSubjects": "14"}]}, {"type": "Received at Least 1 Dose of Study Drug", "achievements": [{"groupId": "FG000", "numSubjects": "14"}, {"groupId": "FG001", "numSubjects": "14"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "12"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}]}, {"title": "Period 2", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "12"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "12"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "All Participants", "description": "All randomized participants who received at least 1 dose of study drug."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "28"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "44.2", "spread": "10.1"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "25"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "3"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "28"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "28"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "classes": [{"title": "Germany", "categories": [{"measurements": [{"groupId": "BG000", "value": "28"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Pharmacodynamics (PD): Plasma Glucose Area Under the Concentration Curve Zero Through 5 Hours (AUC 0-5h), Above Pre Meal Baseline for Insulin Lispro", "description": "To quantitate the pharmacodynamic (PD) effect of a range of prandial insulin lispro doses after treatment with insulin peglispro (LY2605541) compared to insulin glargine during a meal tolerance test (MTT), with sequenced doses of insulin lispro ranging from 25% to 150% of each participant's normal dose. Data presented as hours times milligrams per deciliter (mg\\*h/dL)", "populationDescription": "All participants who received at least 1 dose of study drug and had evaluable PD data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg*h/dL", "timeFrame": "Day 30, 31, 32, 33, 34, pre-breakfast and10,20,30,40,50,60,90,120,150,180,210,240,270, 300 minutes (5 hours) post-breakfast", "groups": [{"id": "OG000", "title": "Insulin Peglispro (LY2605541)", "description": "Insulin peglispro (LY2605541) administered SC daily"}, {"id": "OG001", "title": "Insulin Glargine", "description": "Insulin glargine administered SC daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "26"}]}], "classes": [{"title": "25% Normal Dose", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "26"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "677.84", "spread": "146.48"}, {"groupId": "OG001", "value": "716.52", "spread": "179.89"}]}]}, {"title": "50% Normal Dose", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "25"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "572.96", "spread": "149.76"}, {"groupId": "OG001", "value": "506.22", "spread": "188.54"}]}]}, {"title": "75% Normal Dose", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "25"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "393.28", "spread": "175.68"}, {"groupId": "OG001", "value": "369.08", "spread": "169.08"}]}]}, {"title": "100% Normal Dose", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "25"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "270.46", "spread": "201.73"}, {"groupId": "OG001", "value": "307.81", "spread": "204.27"}]}]}, {"title": "150% Normal Dose", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "25"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "174.38", "spread": "182.00"}, {"groupId": "OG001", "value": "123.97", "spread": "118.82"}]}]}]}, {"type": "SECONDARY", "title": "Pharmacokinetics (PK): Under the Concentration Curve Zero Through 5 Hours (AUC 0-5h) for Prandial Insulin Lispro", "description": "Abbreviation for hours times picomol per liter (pmol\\*h/L)", "populationDescription": "All participants who received at least 1 dose of study drug and had evaluable PK data.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "pmol*h/L", "timeFrame": "Day 29: Pre-breakfast, and 15, 30, 45, 60, 90, 120, 150,180,210,270, and 300 minutes (5 hours) post-breakfast", "groups": [{"id": "OG000", "title": "Insulin Peglispro (LY2605541)", "description": "Insulin peglispro (LY2605541) administered SC daily"}, {"id": "OG001", "title": "Insulin Glargine", "description": "Insulin glargine administered SC daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "21"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "850", "spread": "47"}, {"groupId": "OG001", "value": "852", "spread": "44"}]}]}]}, {"type": "SECONDARY", "title": "Pharmacodynamics (PD): Average Glucose Infusion Rate From Euglycemic 2-step Hyperinsulinemic Clamp (M-value)", "description": "Abbreviation for micro mole per kilogram per minute (\u00b5mol/kg/min). Both arms received insulin lispro in addition to their respective study drug. During the euglycemic 2-step hyperinsulinemic clamp, both low and high insulin was infused sequentially during the same procedure. The 2-step clamp procedure allowed insulin sensitivity to be measured in participants and uses a lower dose of insulin of which the effect is largely on the liver and a high dose of insulin at which the effect has reached 100% on liver and effects are largely on glucose uptake in peripheral tissues. Measurements for average glucose infusion rate are collected for both steps (low and high) of the clamp procedure.", "populationDescription": "All participants who received at least 1 dose of study drug and had evaluable PD data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "\u00b5mol/kg/min", "timeFrame": "Day 35, last 60 minutes of euglycemic 2-step hyperinsulinemic clamp", "groups": [{"id": "OG000", "title": "Insulin Peglispro (LY2605541, With Insulin Lispro)", "description": "Insulin peglispro (LY2605541) once daily subcutaneous (SC) injection at bedtime. Insulin lispro given SC prandially or as bolus as required"}, {"id": "OG001", "title": "Insulin Glargine (With Insulin Lispro)", "description": "Insulin glargine once daily SC injection at bedtime. Insulin lispro given SC prandially or as a bolus as required"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "11"}]}], "classes": [{"title": "High Dose Insulin", "categories": [{"measurements": [{"groupId": "OG000", "value": "52.756", "spread": "11.862"}, {"groupId": "OG001", "value": "56.321", "spread": "10.697"}]}]}, {"title": "Low Dose Insulin", "categories": [{"measurements": [{"groupId": "OG000", "value": "13.908", "spread": "13.181"}, {"groupId": "OG001", "value": "18.765", "spread": "8.293"}]}]}]}, {"type": "SECONDARY", "title": "Pharmacokinetics (PK): Area Under the Concentration Curve From Time Zero to Last Time (AUC [0 Tlast]) for Paracetamol", "populationDescription": "All participants who received at least 1 dose of study drug and had evaluable PK data.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ng*hr/mL", "timeFrame": "Day 29: Pre-breakfast, and 15, 30, 45, 60, 90, 120, 150,180,210,270, and 300 minutes (5 hours) post-breakfast", "groups": [{"id": "OG000", "title": "Insulin Peglispro (LY2605541, With Insulin Lispro)", "description": "Insulin peglispro (LY2605541) once daily subcutaneous (SC) injection at bedtime. Insulin lispro given SC prandially or as bolus as required"}, {"id": "OG001", "title": "Insulin Glargine (With Insulin Lispro)", "description": "Insulin glargine once daily SC injection at bedtime. Insulin lispro given SC prandially or as a bolus as required"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "24"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "33400", "spread": "19"}, {"groupId": "OG001", "value": "33600", "spread": "22"}]}]}]}, {"type": "SECONDARY", "title": "Appetite and Satiety Ratings, as Measured Using Visual Analog Scale (VAS) on Day 29", "description": "VAS was scored from 0 - 100 millimeters (mm) as a perception of appetite and satiety (Flint et al. 2000), 0 being not hungry at all or nothing at all and 100 being extremely hungry and extremely large amount.\n\nThe questions are abbreviated in table from: How hungry do you feel right now? to Hunger and How much food do you think you could eat right now? to Food amount.\n\nDay 29 and cumulative insulin lispro doses of 25%, 50%, 75%, 100% and 150 % of normal insulin lispro dose included.Scores were averaged will be presented and calculated by a sum of the scores dividing by the total by the number of scores reported for timepoints and reported in millimeters.", "populationDescription": "All participants who received at least 1 dose of study drug and had VAS score.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "millimeters (mm)", "timeFrame": "Day 29:Upon waking, pre-breakfast, 1 hour (hr), 2 hr, 3 hr, 4 hr and 5 hr post breakfast", "groups": [{"id": "OG000", "title": "Insulin Peglispro (LY2605541, With Insulin Lispro)", "description": "Insulin peglispro (LY2605541, once daily subcutaneous (SC) injection at bedtime. Insulin lispro given SC prandially or as bolus as required"}, {"id": "OG001", "title": "Insulin Glargine (With Insulin Lispro)", "description": "Insulin glargine once daily SC injection at bedtime. Insulin lispro given SC prandially or as a bolus as required"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "27"}]}], "classes": [{"title": "Day 29: Hunger, waking", "categories": [{"measurements": [{"groupId": "OG000", "value": "27.1", "spread": "22.1"}, {"groupId": "OG001", "value": "32.1", "spread": "26.5"}]}]}, {"title": "Day 29: Hunger, 5 hours post breakfast", "categories": [{"measurements": [{"groupId": "OG000", "value": "53.8", "spread": "27.9"}, {"groupId": "OG001", "value": "58.9", "spread": "24.6"}]}]}, {"title": "Day 29: Food amount, waking", "categories": [{"measurements": [{"groupId": "OG000", "value": "32.5", "spread": "20.6"}, {"groupId": "OG001", "value": "37.7", "spread": "22.8"}]}]}, {"title": "Day 29: Food amount, 5 hours post-breakfast", "categories": [{"measurements": [{"groupId": "OG000", "value": "31.8", "spread": "20.1"}, {"groupId": "OG001", "value": "38.1", "spread": "21.8"}]}]}, {"title": "Overall 25%: Hunger, waking", "categories": [{"measurements": [{"groupId": "OG000", "value": "27.5", "spread": "30.4"}, {"groupId": "OG001", "value": "35.8", "spread": "28.5"}]}]}, {"title": "Overall 25%: Hunger, 5 hours post breakfast", "categories": [{"measurements": [{"groupId": "OG000", "value": "56.1", "spread": "30.7"}, {"groupId": "OG001", "value": "58.0", "spread": "26.2"}]}]}, {"title": "Overall 25%: Food amount, waking", "categories": [{"measurements": [{"groupId": "OG000", "value": "30.8", "spread": "28.9"}, {"groupId": "OG001", "value": "36.4", "spread": "27.6"}]}]}, {"title": "Overall 25%: Food amount, 5 hours post-breakfast", "categories": [{"measurements": [{"groupId": "OG000", "value": "56.5", "spread": "28.0"}, {"groupId": "OG001", "value": "59.0", "spread": "24.9"}]}]}, {"title": "Overall 50%: Hunger, waking", "categories": [{"measurements": [{"groupId": "OG000", "value": "36.0", "spread": "26.2"}, {"groupId": "OG001", "value": "28.2", "spread": "21.9"}]}]}, {"title": "Overall 50%: Hunger, 5 hours post breakfast", "categories": [{"measurements": [{"groupId": "OG000", "value": "56.5", "spread": "26.7"}, {"groupId": "OG001", "value": "64.0", "spread": "25.0"}]}]}, {"title": "Overall 50%: Food amount, waking", "categories": [{"measurements": [{"groupId": "OG000", "value": "37.1", "spread": "25.2"}, {"groupId": "OG001", "value": "31.7", "spread": "21.9"}]}]}, {"title": "Overall 50%: Food amount, 5 hours post-breakfast", "categories": [{"measurements": [{"groupId": "OG000", "value": "55.0", "spread": "24.8"}, {"groupId": "OG001", "value": "64.2", "spread": "23.5"}]}]}, {"title": "Overall 75%: Hunger, waking", "categories": [{"measurements": [{"groupId": "OG000", "value": "29.8", "spread": "25.4"}, {"groupId": "OG001", "value": "30.9", "spread": "27.5"}]}]}, {"title": "Overall 75%: Hunger, 5 hours post breakfast", "categories": [{"measurements": [{"groupId": "OG000", "value": "55.5", "spread": "27.7"}, {"groupId": "OG001", "value": "62.5", "spread": "25.3"}]}]}, {"title": "Overall 75%: Food amount, waking", "categories": [{"measurements": [{"groupId": "OG000", "value": "32.6", "spread": "24.6"}, {"groupId": "OG001", "value": "31.4", "spread": "55.3"}]}]}, {"title": "Overall 75%: Food amount, 5 hours post-breakfast", "categories": [{"measurements": [{"groupId": "OG000", "value": "57.0", "spread": "27.1"}, {"groupId": "OG001", "value": "62.2", "spread": "24.0"}]}]}, {"title": "Overall 100%: Hunger, waking", "categories": [{"measurements": [{"groupId": "OG000", "value": "28.9", "spread": "22.9"}, {"groupId": "OG001", "value": "29.6", "spread": "24.3"}]}]}, {"title": "Overall 100%: Hunger, 5 hours post breakfast", "categories": [{"measurements": [{"groupId": "OG000", "value": "55.0", "spread": "30.2"}, {"groupId": "OG001", "value": "59.0", "spread": "26.9"}]}]}, {"title": "Overall 100%: Food amount, waking", "categories": [{"measurements": [{"groupId": "OG000", "value": "32.3", "spread": "22.9"}, {"groupId": "OG001", "value": "35.7", "spread": "23.7"}]}]}, {"title": "Overall 100%: Food amount, 5 hours post-breakfast", "categories": [{"measurements": [{"groupId": "OG000", "value": "55.3", "spread": "29.1"}, {"groupId": "OG001", "value": "58.6", "spread": "26.4"}]}]}, {"title": "Overall 150%: Hunger, waking", "categories": [{"measurements": [{"groupId": "OG000", "value": "31.4", "spread": "20.4"}, {"groupId": "OG001", "value": "28.5", "spread": "16.9"}]}]}, {"title": "Overall 150%: Hunger, 5 hours post breakfast", "categories": [{"measurements": [{"groupId": "OG000", "value": "52.2", "spread": "27.7"}, {"groupId": "OG001", "value": "58.6", "spread": "28.4"}]}]}, {"title": "Overall 150%: Food amount, waking", "categories": [{"measurements": [{"groupId": "OG000", "value": "34.3", "spread": "17.6"}, {"groupId": "OG001", "value": "34.1", "spread": "17.1"}]}]}, {"title": "Overall 150%: Food amount, 5 hours post-breakfast", "categories": [{"measurements": [{"groupId": "OG000", "value": "52.7", "spread": "25.9"}, {"groupId": "OG001", "value": "58.3", "spread": "26.1"}]}]}]}, {"type": "SECONDARY", "title": "Pharmacodynamics (PD): Area Under the Concentration Zero Through 5 Hours (AUC 0-5h) for Triglycerides", "populationDescription": "All participants who received at least 1 dose of study drug and had evaluable PD data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng*hr/mL", "timeFrame": "Day 29, predose and 15, 30, 45, 60, 90, 120, 150,180,210,270, and 300 minutes (5 hours) post-breakfast", "groups": [{"id": "OG000", "title": "Insulin Peglispro (LY2605541), With Insulin Lispro)", "description": "Insulin peglispro (LY2605541) once daily subcutaneous (SC) injection at bedtime. Insulin lispro given SC prandially or as bolus as required"}, {"id": "OG001", "title": "Insulin Glargine (With Insulin Lispro)", "description": "Insulin glargine once daily SC injection at bedtime. Insulin lispro given SC prandially or as a bolus as required"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "27"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6.85", "spread": "3.13"}, {"groupId": "OG001", "value": "6.01", "spread": "2.22"}]}]}]}, {"type": "SECONDARY", "title": "Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) for Insulin Lispro During Clamp", "description": "During the euglycemic 2-step hyperinsulinemic clamp, both low and high insulin was infused sequentially during the same procedure. The 2-step clamp procedure allowed insulin sensitivity to be measured in participants and uses a lower dose of insulin (Low) of which the effect is largely on the liver and a high dose of insulin (high) at which the effect has reached 100% on liver and effects are largely on glucose uptake in peripheral tissues. AUC is taking during infusion for this outcome measure.", "populationDescription": "All participants who received at least 1 dose of study drug and had evaluable PK data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pmol* hr/L", "timeFrame": "Day 35, insulin clearance during lispro infusion (dosing=infusion)", "groups": [{"id": "OG000", "title": "Insulin Peglispro (LY2605541, With Insulin Lispro)", "description": "Insulin peglispro (LY2605541) once daily subcutaneous (SC) injection at bedtime. Insulin lispro given SC prandially or as bolus as required"}, {"id": "OG001", "title": "Insulin Glargine (With Insulin Lispro)", "description": "Insulin glargine once daily SC injection at bedtime. Insulin lispro given SC prandially or as a bolus as required"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "25"}]}], "classes": [{"title": "Clamp Period 1-3 Hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "243", "spread": "78.9"}, {"groupId": "OG001", "value": "222", "spread": "84.7"}]}]}, {"title": "Clamp Period 4-6 Hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "926", "spread": "335"}, {"groupId": "OG001", "value": "897", "spread": "333"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "description": "All randomized participants.", "eventGroups": [{"id": "EG000", "title": "Insulin Peglispro (LY2605541, With Insulin Lispro)", "description": "Insulin peglispro (LY2605541) once daily subcutaneous (SC) injection at bedtime. Insulin lispro given SC prandially or as bolus as required", "seriousNumAffected": 0, "seriousNumAtRisk": 27, "otherNumAffected": 7, "otherNumAtRisk": 27}, {"id": "EG001", "title": "Insulin Glargine (With Insulin Lispro)", "description": "Insulin glargine once daily SC injection at bedtime. Insulin lispro given SC prandially or as a bolus as required", "seriousNumAffected": 2, "seriousNumAtRisk": 28, "otherNumAffected": 7, "otherNumAtRisk": 28}], "seriousEvents": [{"term": "Viral infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Neuralgic amyotrophy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}]}], "otherEvents": [{"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 28}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 27}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 28}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 27}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 4, "numAtRisk": 27}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 28}]}, {"term": "Phlebitis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 27}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 28}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "GT60", "restrictiveAgreement": true}, "pointOfContact": {"title": "Chief Medical Officer", "organization": "Eli Lilly and Company", "phone": "800-545-5979"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003922", "term": "Diabetes Mellitus, Type 1"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}, {"id": "D000001327", "term": "Autoimmune Diseases"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7117", "name": "Diabetes Mellitus, Type 1", "asFound": "Diabetes Mellitus, Type 1", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}, {"id": "M4629", "name": "Autoimmune Diseases", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000007328", "term": "Insulin"}, {"id": "C000557859", "term": "Insulin, Globin Zinc"}, {"id": "D000069036", "term": "Insulin Glargine"}, {"id": "D000061268", "term": "Insulin Lispro"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M10365", "name": "Insulin", "asFound": "Blood", "relevance": "HIGH"}, {"id": "M173166", "name": "Insulin, Globin Zinc", "asFound": "Blood", "relevance": "HIGH"}, {"id": "M29802", "name": "Insulin Lispro", "asFound": "AUC", "relevance": "HIGH"}, {"id": "M347", "name": "Insulin Glargine", "asFound": "Interaction", "relevance": "HIGH"}, {"id": "M17768", "name": "Zinc", "relevance": "LOW"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Micro", "name": "Micronutrients"}]}}, "hasResults": true}